Galectin-1 Promotes Metastasis in Gastric Cancer Through a Sphingosine-1-Phosphate Receptor 1-Dependent Mechanism

You, Xiaolan; Wang, Yuanjie; Wu, Jian; Liu, Qinghong; Chen, Dehu; Tang, Dong; Wang, Daorong

doi:10.1159/000495157

Cited by 22 publications

(12 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 B, C), suggesting that PRRX1 may promote tumor malignancy by suppressing PKA signaling in human osteosarcoma. Furthermore, our RNA transcriptome data also revealed that PRRX1 knockdown decreased the expression level of S1PR1 that has been reported to be a critical molecule for metastasis [45] , [46] , [47] . Althogh we did not assessed the functional relationship between S1PR1 and PRRX1 in this study, this may be a critical factor to cause the malignancy of osteosarcoma.…”

Section: Discussionsupporting

confidence: 53%

PRRX1 promotes malignant properties in human osteosarcoma

Joko¹,

Yamada

Nakamura

et al. 2021

Translational Oncology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 53%

PRRX1 promotes malignant properties in human osteosarcoma

Joko¹,

Yamada

Nakamura

et al. 2021

Translational Oncology

View full text Add to dashboard Cite

“…Gal-1 is a cell-autocrined protein, which plays an important role in the development and metastasis of many tumors [14]. Some studies have confirmed that Gal-1 is specifically expressed in many tumor tissues and regulates various biological activities of cancer cells, such as breast cancer, gastric cancer [15,16]. However, Gal1 has little research on the role of CRC.…”

Section: Introductionmentioning

confidence: 99%

CHIP-mediated ubiquitination of Galectin-1 predicts colorectal cancer prognosis

et al. 2020

View full text Add to dashboard Cite

CHIP and Galectin-1 are associated with the development of metastasis in cancer. However, the precise roles of CHIP or Gal1 in colorectal cancer are uncertain. Here, our study explored the relationship and clinical significance of CHIP or Gal1 in CRC. CHIP or Gal1 expression was significantly decreased or up-regulated in CRC compared with adjacent noncancerous tissues by immunohistochemistry on a CRC tissue microarray, respectively. Low CHIP or high Gal1 expression significantly correlated with clinicopathological characteristics in patients, as well as with shorter overall survival. Multivariate Cox regression analysis revealed that CHIP or Gal1 expression was an independent prognostic factor for CRC patients. Moreover, CHIP associated with Gal1 has a synergistic effect on the prediction of CRC prognosis. In vitro and vivo, high CHIP or low Gal1 expression inhibit CRC growth or metastasis. Our results found that CHIP could degradate Gal1 by ubiquitination. In summary, CHIP could inhibit CRC growth or metastasis through promoting Gal1 ubiquitination and degradation by proteasome. CHIP and Gal1 expressions are novel candidate prognostic markers in CRC. A combined effect of CHIP and Gal1 as efficient prognostic indicators was found for the first time.

show abstract

“…It interacts with oncogenic H-Ras and promotes cell migration, demonstrating its key role in driving tumor transforming proteins to affect tumor progression, invasion, and angiogenesis (12,13). A large number of studies have suggested that galectin-1 is amplified and highly expressed in thyroid cancer, head and neck cancer, gastric cancer, colon cancer, ovarian cancer, and prostate cancer (14)(15)(16), and the high expression of galectin-1 is correlated with poor prognosis (17)(18)(19). However, few studies have evaluated the relationship between galectin-1 expression and the survival rate of patients with rectal cancer.…”

Section: Discussionmentioning

confidence: 99%

The predictive value of galectin-1 and vascular mimicry in the prognostic evaluation of patients with rectal cancer

Zhou¹,

De-geng²,

Yang³

et al. 2021

Transl Cancer Res TCR

Self Cite

View full text Add to dashboard Cite

Background: This study aims to investigate the expression of galectin-1 and vascular mimicry (VM) in rectal cancer tissues, and to assess their predictive value in the prognostic evaluation of patients with rectal cancer.Methods: Immunohistochemistry (IHC) and CD34-periodic acid solution (PAS) double staining were used to detect galectin-1 expression and the formation of VM in rectal cancer tissues from 94 patients with stage I-III rectal cancer and their corresponding paracancerous tissues. We also analyzed the relationship between the expression of galectin-1, VM, various clinicopathological parameters, and the prognosis of rectal cancer patients, as well as their influence on the overall survival (OS) of rectal cancer patients.Results: Among the 94 tissue specimens from rectal cancer patients, 43 had positive expression of galectin-1 and 19 had positive expression of VM. There was a positive correlation between VM and galectin-1 expression in rectal cancer tissue. Galectin-1 expression in rectal cancer tissue and the formation of VM were related to tumor differentiation, staging, lymph node metastasis, and intravascular tumor thrombus (P<0.05). Kaplan-Meier analysis showed that the OS time of rectal cancer patients in the galectin-1 positive expression group was shorter than the galectin-1 negative expression patients, and the difference between the 2 groups was statistically significant (P=0.003). The OS time of patients with rectal cancer in the VM positive expression group was shorter than the VM negative expression group, and the difference between the two groups was statistically significant (P<0.001). The OS time of the galectin-1 and VM negative expression group was 57.33±1.13 months, and the OS time of the galectin-1 and VM positive expression group was 43.21±3.97 months, while the OS time of the galectin-1 positive expression and VM negative expression group was 55.42±2.23 months, and the difference between the three groups was statistically significant (P<0.001). Multi-factor analysis results indicated that invasion depth and VM expression were independent risk factors that affected the OS of patients with rectal cancer. Conclusions:Galectin-1 and VM expression in rectal cancer tissues may predict poor prognosis in patients after radical surgery. Galectin-1 and VM may therefore become potential new targets for rectal cancer treatment.

show abstract

Galectin-1 Promotes Metastasis in Gastric Cancer Through a Sphingosine-1-Phosphate Receptor 1-Dependent Mechanism

Cited by 22 publications

References 38 publications

PRRX1 promotes malignant properties in human osteosarcoma

PRRX1 promotes malignant properties in human osteosarcoma

CHIP-mediated ubiquitination of Galectin-1 predicts colorectal cancer prognosis

The predictive value of galectin-1 and vascular mimicry in the prognostic evaluation of patients with rectal cancer

Contact Info

Product

Resources

About